WO2023152727A1 - Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases - Google Patents

Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases Download PDF

Info

Publication number
WO2023152727A1
WO2023152727A1 PCT/IB2023/051331 IB2023051331W WO2023152727A1 WO 2023152727 A1 WO2023152727 A1 WO 2023152727A1 IB 2023051331 W IB2023051331 W IB 2023051331W WO 2023152727 A1 WO2023152727 A1 WO 2023152727A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
fact
composition according
weight
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2023/051331
Other languages
French (fr)
Inventor
Angela Maria Pia GUARNIERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silk Medical Srl
Original Assignee
Silk Medical Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silk Medical Srl filed Critical Silk Medical Srl
Priority to EP23709754.8A priority Critical patent/EP4479015A1/en
Publication of WO2023152727A1 publication Critical patent/WO2023152727A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention relates to a dermatological composition and its uses in the cosmetic field and in the treatment of dermatological diseases.
  • the skin is an organ having fundamental importance to the human organism, as it protects from the external environment, is responsible for each person’s aesthetic appearance and tactile sensations.
  • the skin structure functions as an essential barrier to maintain skin hydration within physiological values.
  • the main factors in this barrier that preside over the maintenance of hydration are: the stratum corneum, epidermal lipids, the Natural Moisturizing Factor (NMF) and the surface hydrolipidic film. These components undergo a continuous renewal process related to the ability of keratinocytes in the epidermis to continuously reproduce and differentiate, thus shaping the various layers that make up the epidermis.
  • NMF Natural Moisturizing Factor
  • the main factors of dehydration are of the chemical type (e.g., the solvent and delipidizing action related to the repeated application of surfactants) or related to unfavorable climatic and environmental conditions: wind, cold and humidity of environments, when intervening separately or jointly, cause dehydration of the stratum corneum with the formation of dry, rough, flaky, cracked skin, redness, itching and other irritative phenomena.
  • dry skin can be caused by endogenous factors of hormonal, dietary and pharmacological origin.
  • endogenous factors of a pharmacological origin The management of the adverse effects related to endogenous factors of a pharmacological origin, is considerably complicated since, the occurrence of skin disorders, often turns out to be a secondary aspect to the patient’s main clinical picture.
  • compositions suitable for the treatment of dry, reddened and cracked skin that are alcohol-based but comprising additives of synthetic origin that do not meet the requirements of tolerability, safety and efficacy needed for the skin of oncology patients.
  • compositions specifically formulated for the prevention and treatment of dermatitis caused by anti-cancer therapies such as chemotherapy and radiation therapy.
  • the main aim of the present invention is to devise a dermatological composition that meets the requirements of tolerability, safety and efficacy needed for dry and cracked skin, particularly but not limited to oncology patients.
  • Another object of the present invention is to devise a dermatological composition free of synthetic substances and entirely consisting of natural components.
  • Another object of the present invention is to devise a dermatological composition which is easily applicable and rapidly absorbed.
  • Another object of the present invention is to devise a dermatological composition which allows the aforementioned drawbacks of the prior art to be overcome within the framework of a simple, rational, easy and efficient to use as well as cost-effective solution.
  • the present invention relates to a dermatological composition.
  • the composition in accordance with the present invention comprises: water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; at least one hydrolyzed extract of silk proteins present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 15%; at least one antioxidant agent; at least one preservative agent present in a concentration by weight, evaluated with respect to the total weight of the composition, less than 5%.
  • the hydrolyzed extract of silk proteins consists of a fibroin hydrolyzed extract.
  • the fibroin hydrolyzed extract is present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 25%.
  • thermal water refers to water obtained from thermal sources.
  • Thermal water consists of thermal water comprising at least two of: calcium, magnesium, iron, manganese, silicon, copper and zinc.
  • thermal water in accordance with the present invention comprises: calcium, magnesium, iron, manganese, silicon, copper and zinc.
  • thermal water greatly increases the functional value of the invention, as the synergistic presence of the aforementioned elements allows the skin to be hydrated and purified, thus accelerating the healing processes thereof from dermatitis.
  • the presence of silicon increases the antioxidant power of the composition in accordance with the present invention, thus stimulating cell regeneration.
  • thermal water is present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 35%.
  • the hydrolyzed extract comprises fibroin in a concentration by weight, evaluated with respect to the total weight of the extract, comprised between 2% and 15%.
  • the hydrolyzed extract comprises fibroin in a concentration by weight, evaluated with respect to the total weight of the extract, comprised between 4% and 12%.
  • fibroin in the composition in accordance with the present invention allows oxygen exchanges with the outside world, thus ensuring optimal skin homeostasis.
  • a fibroin hydrolyzed extract allows sterilization of the composition in accordance with the present invention, thus preventing degradation of the components contained therein.
  • a fibroin hydrolyzed extract allows the stimulation of collagen production and thus the reproduction of fibroblasts so it performs a regenerative activity on the skin, synergistically with antibacterial, antifungal and antiviral activity by attacking and destroying the membrane of the pathogenic microorganisms on the skin.
  • a fibroin hydrolyzed extract fights against skin redness and erythema, performs a reparative function on scars and keloids, deeply moisturizing the tissues and allowing its use even in the presence of viral and herpetic infections.
  • the antioxidant agent comprises tocopherols.
  • the antioxidant agent is Vitamin E or, alternatively, tocopheryl acetate.
  • the preservative agent comprises at least one of citric acid, benzyl alcohol, benzoic acid, capryloyl glycol, or mixtures thereof, present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 1%.
  • composition according to the invention comprises at least one emollient agent selected from the list comprising: ethylhexyl palmitate, glycerin, ethylhexyl stearate, undecane, tridecane, ethylhexyl palmitate, caprylic/capric triglyceride, ethylhexylglycerin or mixtures thereof.
  • emollient agent selected from the list comprising: ethylhexyl palmitate, glycerin, ethylhexyl stearate, undecane, tridecane, ethylhexyl palmitate, caprylic/capric triglyceride, ethylhexylglycerin or mixtures thereof.
  • the at least one emollient agent is present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 8%.
  • composition comprises at least one emulsifying agent selected from the list comprising: cetyl alcohol, cetylstearyl alcohol, glyceryl stearate citrate, shea butter or mixtures thereof.
  • the composition comprises at least one thickening agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 3%.
  • the at least one thickening agent comprises: xanthan gum, propylene glycol or mixtures thereof.
  • composition according to the invention comprises at least one chelating agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 5%.
  • the chelating agent comprises tetrasodium glutamate diacetate.
  • composition comprises at least one antimicrobial agent comprising, in turn, at least one of: phenoxyethanol and lactic acid.
  • composition in accordance with the present invention comprises at least one of freeze-dried annone pulp extract, beeswax, alba wax, turmeric essential oil, rice starch and vitamin A.
  • the composition is in creamy form and comprises: freeze-dried annone extract, one of either beeswax or Alba wax, Turmeric essential oil and rice starch.
  • freeze-dried annone extract has the following properties: anti- aging; antioxidant due to the presence of polyphenols having anti-cancer action; healing and cell regeneration; antiviral.
  • freeze-dried annone extract comprises folic acid and vitamins C and B.
  • beeswax or Alba wax has the following properties: hydrophobic and protective on the stratum corneum by preventing excessive water loss from the skin; emollient; emulsifier between water and oil; soothing to the skin; antibacterial.
  • beeswax or Alba wax is present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 10%, preferably less than 5%.
  • Turmeric essential oil has the following properties: preservative, antioxidant, sebum regulator, antibacterial, antiviral, antifungal, anti-cancer, anti-allergic and anti-aging.
  • the rice starch powder has the following properties: refreshing, soothing and anti-itching.
  • rice starch makes it possible to increase the density of the cream, acting as a natural thickener and avoiding the use of synthetic thickening agents.
  • the composition is in liquid form and comprises vitamin A.
  • both embodiments of the composition according to the invention comprise thermal water, fibroin hydrolyzed extract, vitamin E and citric acid.
  • the dermatological composition in creamy form and that in liquid form differ from each other, the former, by the characteristic presence of annone pulp, beeswax or Alba wax, Turmeric essential oil and rice starch, while the latter by the presence of Vitamin A.
  • composition in accordance with this invention fibroin hydrolysate: 20%. water: 50%-75%; fibroin hydrolysate: 20%; ethylhexyl palmitate: l%-5%; glycerin: 3%; ethylhexyl stearate: l%-5%; undecane and tridecane: 0.1 %- 1 %; caprylic/capric triglyceride: l%-5%; cetyl alcohol: l%-5%; cetylstearyl alcohol: l%-5%; glyceryl stearate citrate: l%-5%; shea butter: 1%; xanthan gum:0.1%-l%; benzyl alcohol, benzoic acid, caprylic glycol: 0.1%-1%; tetrasodium glutamate diacetate: 0.1 %- 1 % .
  • EXAMPLE 1 dermatological composition in creamy form. thermal water: 35%; fibroin hydrolyzed extract titrated to 4%: 30%; freeze-dried annone pulp extract: 10%; beeswax or Alba wax 2.5%;
  • Turmeric essential oil 10%;
  • Vitamin E 6% rice starch: 6% citric acid: 0.5%.
  • EXAMPLE 2 dermatological composition in liquid form. thermal water: 35%; fibroin hydrolyzed extract titrated to 6%: 40%; vitamin A: 15%; vitamin E: 9.2%; citric acid: 0.8%.
  • the present invention relates to the use of the composition in the prevention and treatment of dermatitis caused by anti-cancer drugs.
  • the present invention relates to the use of the composition in the cosmetic field.
  • the present invention relates to a dermatological kit comprising the dermatological composition in creamy form and the dermatological composition in liquid form.
  • compositions surprisingly allows the drawbacks of known compositions to be overcome, namely the unsuitability for the treatment of sensitive and dehydrated skin characteristic of patients undergoing cancer therapies.
  • composition in accordance with the present invention gives high degree of hydration and oxygenation of the skin tissues that undergo biochemical and structural changes as a result of cancer therapies.
  • composition according to the invention in creamy form has a particularly fluid texture compared to creams currently on the market, allowing it to be applied not only to the face but also to other areas such as, e.g., chest, legs, arms or back.
  • composition according to the invention in liquid form has improved absorption, allowing its application even on sensitive skin altered by cancer treatments.
  • this composition has a high antibacterial and antifungal activity since the tissues are subjected to not only environmental but also therapeutic stresses, the skin of oncology patients being characterized by altered vascularization, fragility and having an altered pH due to the homeostatic skin alteration caused by anti-cancer therapies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dermatological composition comprising: - water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; - at least one hydrolyzed extract of silk proteins present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 15%; - at least one antioxidant agent; - at least one preservative agent present in a concentration by weight, evaluated with respect to the total weight of the composition, less than 5%. Said composition for use in the prevention and treatment of dermatitis caused by anti-cancer drugs.

Description

DERMATOLOGICAL COMPOSITION COMPRISING SILK PROTEINS AND ITS USES IN THE COSMETIC FIELD AND IN THE TREATMENT OF DERMATOLOGICAL DISEASES
Technical Field The present invention relates to a dermatological composition and its uses in the cosmetic field and in the treatment of dermatological diseases.
Background Art
As is well known, the skin is an organ having fundamental importance to the human organism, as it protects from the external environment, is responsible for each person’s aesthetic appearance and tactile sensations.
The skin structure functions as an essential barrier to maintain skin hydration within physiological values. The main factors in this barrier that preside over the maintenance of hydration are: the stratum corneum, epidermal lipids, the Natural Moisturizing Factor (NMF) and the surface hydrolipidic film. These components undergo a continuous renewal process related to the ability of keratinocytes in the epidermis to continuously reproduce and differentiate, thus shaping the various layers that make up the epidermis.
Various exogenous and endogenous factors can alter these delicate defense mechanisms, causing more or less pronounced states of skin dehydration. The level of skin hydration varies depending on moisture, the hygroscopic properties of the stratum corneum and the presence of naturally moisturizing factors, in the absence of which the phenomenon of skin dryness sets in.
In addition to age and genetic predisposition for skin aging, numerous external factors can cause more or less pronounced states of skin dehydration. The main factors of dehydration are of the chemical type (e.g., the solvent and delipidizing action related to the repeated application of surfactants) or related to unfavorable climatic and environmental conditions: wind, cold and humidity of environments, when intervening separately or jointly, cause dehydration of the stratum corneum with the formation of dry, rough, flaky, cracked skin, redness, itching and other irritative phenomena.
In addition to exogenous factors, age and genetic predisposition, dry skin can be caused by endogenous factors of hormonal, dietary and pharmacological origin. The management of the adverse effects related to endogenous factors of a pharmacological origin, is considerably complicated since, the occurrence of skin disorders, often turns out to be a secondary aspect to the patient’s main clinical picture.
In addition, it should be considered that the severity of skin dryness increases as the concomitant causes increase.
This is the case for oncology patients, where the use of anti-cancer therapies causes damaging effects on patients’ skin that, however, are of less clinical importance than the management of an oncological framework of main importance, but which also contributes to increased dehydration and skin sensitivity.
Precisely this type of patients needs products that are effective but, at the same time, contain natural ingredients characterized by the absence of heavy metals, parabens, synthetic chemicals and the presence of ingredients with high antioxidant power which can fight the oxidative stress brought about by free radicals produced in abundance by the pharmacological treatments to which oncology patients are subjected.
At present, there are known dermatological compositions suitable for the treatment of dry, reddened and cracked skin that are alcohol-based but comprising additives of synthetic origin that do not meet the requirements of tolerability, safety and efficacy needed for the skin of oncology patients.
Thus, there is a particular need to develop dermatological compositions specifically formulated for the prevention and treatment of dermatitis caused by anti-cancer therapies such as chemotherapy and radiation therapy.
Description of the Invention
The main aim of the present invention is to devise a dermatological composition that meets the requirements of tolerability, safety and efficacy needed for dry and cracked skin, particularly but not limited to oncology patients.
Another object of the present invention is to devise a dermatological composition free of synthetic substances and entirely consisting of natural components.
Another object of the present invention is to devise a dermatological composition which is easily applicable and rapidly absorbed.
Another object of the present invention is to devise a dermatological composition which allows the aforementioned drawbacks of the prior art to be overcome within the framework of a simple, rational, easy and efficient to use as well as cost-effective solution.
The aforementioned objects are achieved by this dermatological composition having the characteristics of claim 1.
In addition, the aforementioned objects are achieved by the dermatological kit having the characteristics of claim 10.
Embodiments of the Invention
In a first aspect, the present invention relates to a dermatological composition.
The composition in accordance with the present invention comprises: water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; at least one hydrolyzed extract of silk proteins present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 15%; at least one antioxidant agent; at least one preservative agent present in a concentration by weight, evaluated with respect to the total weight of the composition, less than 5%.
In accordance with a preferred embodiment, the hydrolyzed extract of silk proteins consists of a fibroin hydrolyzed extract.
Preferably, the fibroin hydrolyzed extract is present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 25%.
It is specified that within the scope of this disclosure the expression “thermal water” refers to water obtained from thermal sources.
Water consists of thermal water comprising at least two of: calcium, magnesium, iron, manganese, silicon, copper and zinc. Preferably, thermal water in accordance with the present invention comprises: calcium, magnesium, iron, manganese, silicon, copper and zinc.
The presence of thermal water greatly increases the functional value of the invention, as the synergistic presence of the aforementioned elements allows the skin to be hydrated and purified, thus accelerating the healing processes thereof from dermatitis.
In addition, the presence of iron increases skin oxygenation.
Still, the presence of silicon increases the antioxidant power of the composition in accordance with the present invention, thus stimulating cell regeneration.
In addition, the presence of silicon tones the skin, allowing an anti- aging effect, the presence of copper alleviates inflammatory processes and finally, zinc alleviates skin irritation.
Preferably, thermal water is present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 35%.
Advantageously, the hydrolyzed extract comprises fibroin in a concentration by weight, evaluated with respect to the total weight of the extract, comprised between 2% and 15%.
Precisely, the hydrolyzed extract comprises fibroin in a concentration by weight, evaluated with respect to the total weight of the extract, comprised between 4% and 12%.
The presence of fibroin in the composition in accordance with the present invention allows oxygen exchanges with the outside world, thus ensuring optimal skin homeostasis.
In addition, the presence of a fibroin hydrolyzed extract allows sterilization of the composition in accordance with the present invention, thus preventing degradation of the components contained therein.
Finally, the presence of a fibroin hydrolyzed extract allows the stimulation of collagen production and thus the reproduction of fibroblasts so it performs a regenerative activity on the skin, synergistically with antibacterial, antifungal and antiviral activity by attacking and destroying the membrane of the pathogenic microorganisms on the skin. Finally, it should be emphasized that the presence of a fibroin hydrolyzed extract fights against skin redness and erythema, performs a reparative function on scars and keloids, deeply moisturizing the tissues and allowing its use even in the presence of viral and herpetic infections.
Preferably, the antioxidant agent comprises tocopherols.
In detail, the antioxidant agent is Vitamin E or, alternatively, tocopheryl acetate. Advantageously, the preservative agent comprises at least one of citric acid, benzyl alcohol, benzoic acid, capryloyl glycol, or mixtures thereof, present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 1%.
In addition, the composition according to the invention comprises at least one emollient agent selected from the list comprising: ethylhexyl palmitate, glycerin, ethylhexyl stearate, undecane, tridecane, ethylhexyl palmitate, caprylic/capric triglyceride, ethylhexylglycerin or mixtures thereof.
Advantageously, the at least one emollient agent is present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 8%.
In addition, the composition comprises at least one emulsifying agent selected from the list comprising: cetyl alcohol, cetylstearyl alcohol, glyceryl stearate citrate, shea butter or mixtures thereof.
In addition, the composition comprises at least one thickening agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 3%.
Preferably, the at least one thickening agent comprises: xanthan gum, propylene glycol or mixtures thereof.
Again, the composition according to the invention comprises at least one chelating agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 5%.
In accordance with a preferred embodiment, the chelating agent comprises tetrasodium glutamate diacetate.
In addition, the composition comprises at least one antimicrobial agent comprising, in turn, at least one of: phenoxyethanol and lactic acid.
Still, the composition in accordance with the present invention comprises at least one of freeze-dried annone pulp extract, beeswax, alba wax, turmeric essential oil, rice starch and vitamin A.
In accordance with a first embodiment according to the invention, the composition is in creamy form and comprises: freeze-dried annone extract, one of either beeswax or Alba wax, Turmeric essential oil and rice starch.
Advantageously, the presence of freeze-dried annone extract has the following properties: anti- aging; antioxidant due to the presence of polyphenols having anti-cancer action; healing and cell regeneration; antiviral.
In addition, the freeze-dried annone extract comprises folic acid and vitamins C and B.
At the same time, beeswax or Alba wax has the following properties: hydrophobic and protective on the stratum corneum by preventing excessive water loss from the skin; emollient; emulsifier between water and oil; soothing to the skin; antibacterial.
Advantageously, beeswax or Alba wax is present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 10%, preferably less than 5%.
In addition, it should be emphasized that the presence of Turmeric essential oil has the following properties: preservative, antioxidant, sebum regulator, antibacterial, antiviral, antifungal, anti-cancer, anti-allergic and anti-aging.
Preferably, the rice starch powder has the following properties: refreshing, soothing and anti-itching.
In addition, the presence of rice starch makes it possible to increase the density of the cream, acting as a natural thickener and avoiding the use of synthetic thickening agents.
In accordance with a second embodiment according to the invention, the composition is in liquid form and comprises vitamin A.
In detail, both embodiments of the composition according to the invention comprise thermal water, fibroin hydrolyzed extract, vitamin E and citric acid.
The dermatological composition in creamy form and that in liquid form differ from each other, the former, by the characteristic presence of annone pulp, beeswax or Alba wax, Turmeric essential oil and rice starch, while the latter by the presence of Vitamin A.
The following is a generic example of composition in accordance with this invention: fibroin hydrolysate: 20%. water: 50%-75%; fibroin hydrolysate: 20%; ethylhexyl palmitate: l%-5%; glycerin: 3%; ethylhexyl stearate: l%-5%; undecane and tridecane: 0.1 %- 1 %; caprylic/capric triglyceride: l%-5%; cetyl alcohol: l%-5%; cetylstearyl alcohol: l%-5%; glyceryl stearate citrate: l%-5%; shea butter: 1%; xanthan gum:0.1%-l%; benzyl alcohol, benzoic acid, caprylic glycol: 0.1%-1%; tetrasodium glutamate diacetate: 0.1 %- 1 % .
Two examples of the composition in accordance with the present invention are given below.
It is specified that the percentage concentrations given below are intended with respect to the total weight of the composition; in detail, by way of example, the aforementioned percentages refer to 100 ml of product.
EXAMPLE 1 - dermatological composition in creamy form. thermal water: 35%; fibroin hydrolyzed extract titrated to 4%: 30%; freeze-dried annone pulp extract: 10%; beeswax or Alba wax 2.5%;
Turmeric essential oil: 10%;
Vitamin E: 6% rice starch: 6% citric acid: 0.5%.
EXAMPLE 2 - dermatological composition in liquid form. thermal water: 35%; fibroin hydrolyzed extract titrated to 6%: 40%; vitamin A: 15%; vitamin E: 9.2%; citric acid: 0.8%.
In a further aspect, the present invention relates to the use of the composition in the prevention and treatment of dermatitis caused by anti-cancer drugs.
In another aspect, the present invention relates to the use of the composition in the cosmetic field.
Finally, the present invention relates to a dermatological kit comprising the dermatological composition in creamy form and the dermatological composition in liquid form.
The combined use of the aforementioned compositions surprisingly allows the drawbacks of known compositions to be overcome, namely the unsuitability for the treatment of sensitive and dehydrated skin characteristic of patients undergoing cancer therapies.
It has in practice been ascertained that the described invention achieves the intended objects.
It is emphasized that the synergistic combination of a fibroin freeze-dried extract in combination with thermal water and one or more of the components listed above makes it possible to obtain a dermatological composition that is neither sensitizing in the short, or medium, or long term but, rather, that is adapted to counteract skin hyperemia or erythema, dehydration and tissue changes brought about by antitumor therapies carried out in order to restore the hydrolipidic skin film.
In particular, the composition in accordance with the present invention gives high degree of hydration and oxygenation of the skin tissues that undergo biochemical and structural changes as a result of cancer therapies.
In detail, the composition according to the invention in creamy form has a particularly fluid texture compared to creams currently on the market, allowing it to be applied not only to the face but also to other areas such as, e.g., chest, legs, arms or back.
In addition, the composition according to the invention in liquid form has improved absorption, allowing its application even on sensitive skin altered by cancer treatments.
In addition, this composition has a high antibacterial and antifungal activity since the tissues are subjected to not only environmental but also therapeutic stresses, the skin of oncology patients being characterized by altered vascularization, fragility and having an altered pH due to the homeostatic skin alteration caused by anti-cancer therapies.

Claims

1) Dermatological composition, characterized by the fact that it comprises: water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; at least one hydrolyzed extract of silk proteins present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 15%; at least one antioxidant agent; at least one preservative agent present in a concentration by weight, evaluated with respect to the total weight of the composition, less than 5%.
2) Composition according to claim 1, characterized by the fact that said hydrolyzed extract of silk proteins consists of a fibroin hydrolyzed extract.
3) Composition according to one or more of the preceding claims, characterized by the fact that said hydrolyzed extract comprises fibroin in a concentration by weight, evaluated with respect to the total weight of the extract, comprised between 2% and 15%.
4) Composition according to one or more of the preceding claims, characterized by the fact that said fibroin hydrolyzed extract is present in a concentration greater than 25%.
5) Composition according to one or more of the preceding claims, characterized by the fact that said water consists of thermal water comprising at least two of: calcium, magnesium, iron, manganese, silicon, copper and zinc.
6) Composition according to one or more of the preceding claims, characterized by the fact that said at least one antioxidant agent comprises tocopherols.
7) Composition according to one or more of the preceding claims, characterized by the fact that said preservative agent comprises at least one of: citric acid, benzyl alcohol, benzoic acid, capryloyl glycol or mixtures thereof, present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 1%.
8) Cosmetic composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one of freeze-dried annone pulp extract, beeswax or alba wax, turmeric essential oil, rice starch and vitamin A.
9) Composition according to one or more of the preceding claims, for use in the prevention and treatment of dermatitis caused by anti-cancer drugs.
10) Composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one emollient agent selected from the list comprising: ethylhexyl palmitate, glycerin, ethylhexyl stearate, undecane, tridecane, ethylhexyl palmitate, caprylic/capric triglyceride, ethylhexylglycerin or mixtures thereof.
11) Composition according to one or more of the preceding claims, characterized by the fact that said at least one emollient agent is present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 8%.
12) Composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one emulsifying agent selected from the list comprising: cetyl alcohol, cetylstearyl alcohol, glyceryl stearate citrate, shea butter or mixtures thereof.
13) Composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one thickening agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 3%.
14) Composition according to one or more of the preceding claims, characterized by the fact that said at least one thickening agent comprises: xanthan gum, propylene glycol.
15) Composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one chelating agent present in a concentration by weight, evaluated with respect to the total weight of the composition, of less than 5%.
16) Composition according to one or more of the preceding claims, characterized by the fact that said chelating agent comprises tetrasodium glutamate diacetate.
17) Composition according to one or more of the preceding claims, characterized by the fact that it comprises at least one antimicrobial agent comprising, in turn, at least one of: phenoxyethanol and lactic acid. 18) Dermatological composition according to one or more of the preceding claims, characterized by the fact that it is in creamy form and comprises said freeze-dried annon extract, said beeswax or Alba wax, said Turmeric essential oil and said rice starch.
19) Dermatological composition according to one or more of claims 1-17, characterized by the fact that it is in liquid form and comprises said vitamin A.
20) Dermatological kit comprising: said dermatological composition in creamy form according to claim 18; said dermatological composition in liquid form according to claim 19.
PCT/IB2023/051331 2022-02-14 2023-02-14 Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases Ceased WO2023152727A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23709754.8A EP4479015A1 (en) 2022-02-14 2023-02-14 Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102022000002684A IT202200002684A1 (en) 2022-02-14 2022-02-14 DERMATOLOGICAL COMPOSITION AND ITS USES IN THE COSMETIC FIELD AND IN THE TREATMENT OF DERMATOLOGICAL DISEASES
IT102022000002684 2022-02-14

Publications (1)

Publication Number Publication Date
WO2023152727A1 true WO2023152727A1 (en) 2023-08-17

Family

ID=81392663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/051331 Ceased WO2023152727A1 (en) 2022-02-14 2023-02-14 Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases

Country Status (3)

Country Link
EP (1) EP4479015A1 (en)
IT (1) IT202200002684A1 (en)
WO (1) WO2023152727A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081021A (en) * 1999-09-09 2001-03-27 Ichimaru Pharcos Co Ltd Cosmetic composition
US20090042846A1 (en) * 2005-08-19 2009-02-12 Bioderm Research Topical Delivery System for Phytosterols
WO2013159101A1 (en) * 2012-04-20 2013-10-24 Trustees Of Tufts College Silk fibroin-based personal care compositions
US20170216171A1 (en) * 2006-02-10 2017-08-03 Dupont Tate & Lyle Bio Products Company, Llc Biodegradable compositions comprising renewably-based, biodegradable 1,3-propanediol
US9732071B2 (en) * 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
CN107072916A (en) * 2014-11-10 2017-08-18 昭和电工株式会社 moisturizer
WO2021035087A1 (en) * 2019-08-20 2021-02-25 Evolved By Nature, Inc. Silk personal care compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081021A (en) * 1999-09-09 2001-03-27 Ichimaru Pharcos Co Ltd Cosmetic composition
US20090042846A1 (en) * 2005-08-19 2009-02-12 Bioderm Research Topical Delivery System for Phytosterols
US20170216171A1 (en) * 2006-02-10 2017-08-03 Dupont Tate & Lyle Bio Products Company, Llc Biodegradable compositions comprising renewably-based, biodegradable 1,3-propanediol
WO2013159101A1 (en) * 2012-04-20 2013-10-24 Trustees Of Tufts College Silk fibroin-based personal care compositions
CN107072916A (en) * 2014-11-10 2017-08-18 昭和电工株式会社 moisturizer
US9732071B2 (en) * 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
WO2021035087A1 (en) * 2019-08-20 2021-02-25 Evolved By Nature, Inc. Silk personal care compositions

Also Published As

Publication number Publication date
IT202200002684A1 (en) 2023-08-14
EP4479015A1 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
JP4880816B2 (en) Skin anti-aging agent
JP2001502685A (en) Use of a conjugate for the manufacture of a composition for the treatment of sensitive skin, method of manufacture and hypoallergenic compositions
GB2451224A (en) Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser
GB2445265A (en) Skin rejuvenation cream
CN102421412B (en) Composition containing chamaecyparis obtusa polysaccharides to be externally applied to skin
US11090205B2 (en) Methods and compositions for treatment of skin conditions
US9468597B1 (en) Stabilized L-ascorbic acid skin serum
KR102142311B1 (en) Skin external composition comprising tangeretin
CN104434642B (en) An after-sun repairing, whitening and moisturizing gel and its preparation method
US11918666B2 (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
CN118319813A (en) Astaxanthin anti-acne skin care composition and preparation method thereof
EP1670430A2 (en) Cosmetic and hygiene products containing deuterium-depleted water
CN103494737A (en) Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation
US20020176876A1 (en) Topical therapeutic skin care system
WO2023152727A1 (en) Dermatological composition comprising silk proteins and its uses in the cosmetic field and in the treatment of dermatological diseases
KR102801893B1 (en) Composition for treating acne containing nanoized bee pollen extract as an active ingredient
KR102670049B1 (en) Cosmetic composition for exfoliating and pad having the same
US11058615B1 (en) Cosmetic dermal serum with skin rejuvenation properties
EP4085913A1 (en) Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea
BG3819U1 (en) Dermatological agent
KR102908170B1 (en) Cosmetic composition for infants for skin sedation conatining mixed grain extract as an active ingredient
Veloso et al. Honey: Chemical Composition and Moisturizing Potential for The Skin–A Review
US20250090443A1 (en) Skin care compositions and their uses
KR20040056080A (en) Cosmetic composition for preventing and therapeutic for a pimple
KR20190132197A (en) Cosmetic composition for use in the treatment and prevention of acne-prone skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23709754

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023709754

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023709754

Country of ref document: EP

Effective date: 20240916